Pro-Dex, Inc. — Form 10-Q Summary
Business context and reporting period
The filing covers the three and nine months ended March 31, 2016, Pro-Dex’s fiscal third quarter and year to date. The supplied metadata labels the period “2015 Q3,” but the filing itself reports fiscal 2016 results. Pro-Dex makes medical and dental instruments, motion-control products, injection molds, and engineering staffing services. Figures below are in U.S. dollars; financial statement amounts are generally in thousands.
Financial performance and liquidity
| Metric | Three months ended March 31, 2016 | Nine months ended March 31, 2016 |
|---|---|---|
| Revenue | $5.337 million, up 36% year over year | $14.873 million, up 60% |
| Gross profit / margin | $1.360 million / 25%; prior-year margin 27% | $3.957 million / 27%; prior-year margin 28% |
| Operating income (loss) | $50,000; prior-year loss of $390,000 | $327,000; prior-year loss of $973,000 |
| Net income (loss) | $368,000; prior-year loss of $76,000 | $633,000; prior-year loss of $438,000 |
| Basic and diluted EPS | $0.09; prior-year loss per share of $0.02 | $0.15; prior-year loss per share of $0.10 |
Revenue growth was led by medical-device products and services, which generated $3.864 million in the quarter and $10.521 million year to date. Gross margins declined as newer medical products had lower margins and incurred added labor and overhead during production ramp-up. Quarterly results included a $340,000 gain from the Ramsey investment/property sale and a $245,000 non-cash impairment charge related to Fineline goodwill and its trade name.
For the nine months, operating cash flow was negative $1.039 million, compared with negative $438,000 a year earlier. Investing activities provided $1.794 million, principally from Ramsey-related asset sales; financing cash flow was zero. Cash was $1.452 million at March 31, 2016, versus $697,000 at June 30, 2015. Working capital was $7.517 million. Total liabilities were $2.377 million. The company had no Summit revolving-loan borrowings outstanding at quarter-end; the remaining Fineline note payable was approximately $76,000.
Material changes versus the prior comparable period
- Medical-device and service sales increased substantially, including shipments of recently launched surgical devices and recognition of previously deferred development revenue. This was partly offset by lower sales to a long-standing customer whose orthopedic-shaver deliveries were extended through December 2016.
- Three customers accounted for 56% of quarterly revenue and 57% of nine-month revenue. Management also reported an approximately $11.2 million backlog at March 2016, with $6.3 million scheduled for fiscal 2017.
- OMS revenue and operating income declined; Fineline recorded operating losses, including the impairment charge. Pro-Dex was the primary profitable operating segment.
- The company sold the Ramsey property and related collateral, recognized a $340,000 gain, and repaid the $500,000 Fortitude loan. It also moved Huber production from San Carlos to Irvine.
- Operating expenses totaled $1.310 million for the quarter, including impairment, versus $1.435 million a year earlier. General and administrative and selling expenses decreased; research and development was broadly stable year to date.
Outlook, commentary, and risks
Management expected existing cash, receivables, and the Summit receivables-based facility to fund operations for at least the next 12 months, while cautioning that additional debt or equity financing may be needed if working-capital requirements grow. The Summit facility permits borrowing up to $1.0 million, at prime plus 2% plus an administrative fee, and carries an annual facility fee.
Management’s priorities include protecting key medical-device relationships, reducing costs on newer products, completing development projects, integrating acquisitions, and growing engineering-services revenue. It anticipated another engineering project completion and potential product launch in fiscal 2017, but provided no quantified earnings or revenue guidance. Risks include negative operating cash flow, long-lead-time materials, customer cancellations or late payment, customer concentration, demand changes, lower margins on newer products, and competition and rapid technological change. Management reported disclosure controls were effective and no material changes in internal control over financial reporting. It described ongoing legal proceedings as incidental and not currently material.
Important facts for investors to verify
- Whether the reported backlog converts to shipments and cash on schedule, especially the fiscal 2017 portion.
- Whether newer medical-device products achieve improved margins as production scales, and whether cost-reduction efforts succeed.
- Exposure to the three major customers, including the declining orthopedic-shaver demand and delivery schedule through December 2016.
- Cash conversion and working-capital trends: operating cash use continued despite reported net income, while cash increased largely through asset-sale proceeds.
- Fineline’s operating performance and the assumptions underlying its goodwill and intangible-asset impairment valuation.
- Availability and terms of additional financing if cash needs exceed current resources or the Summit facility.